Phase 2 trial: ATIR for blood cancer following haploidentical hematopoietic cell transplantation - 101793

Spotlight
Video

Phase 2 trial: ATIR for blood cancer following haploidentical hematopoietic cell transplantation

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: At the 58th American Society of Hematology (ASH) Annual Meeting & Exposition, Roy Denis-Claude, MD, from Maisonneuve-Rosemont Hospital and Montreal University, Montreal, QC, Canada, discusses the results of an open-label, multi-center phase 2 clinical trial, which showed donor lymphocytes depleted of alloreactive T cells (ATIR101) reduced transplant-related mortality and improved overall survival in haploidentical hematopoietic stem cell transplantation (HSCT) for patients with high-risk acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL), using an immunosuppressant-free transplant regimen.
Shared By : VJHemOnc
Posted on : 02/11/16
Added : 3 years ago